Abstract
Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement and fatal systemic infection. WHO estimates that the disease results in 2 million new cases a year, threatens 350 million people in 88 countries and that there are 12 million people currently infected worldwide. Current treatment is based on chemotherapy, which relies on a handful of drugs with serious limitations such as high cost, toxicity, difficult route of administration and lack of efficacy in endemic areas. Pentavalent antimonials have been the mainstay of antileishmanial therapy for over 70 years with second line drugs, Amphotericin B and Pentamidine, used in case of antimonial failure. Since the introduction of miltefosine at the beginning of this century, no new antileishmanial compounds have been approved for human treatment. Leishmaniasis is considered one of a few parasitic diseases likely to be controllable by vaccination. However, to date no such vaccine is available despite substantial efforts by many laboratories. The development of a safe, effective and affordable antileishmanial vaccine is a critical global public-health priority. This review outlines the current status of vaccine development and looks at the currently available chemotherapy as well as examples of drugs in development and different approaches to antileishmanial drug discovery and identification of novel antiparasitic compounds.
Keywords: Leishmaniasis, antileishmanial drugs, antileishmanial vaccine, immunology, chemotherapy, drug target
Current Medicinal Chemistry
Title: Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines
Volume: 16 Issue: 5
Author(s): Lukasz Kedzierski, Anuratha Sakthianandeswaren, Joan M. Curtis, Philip C. Andrews, Peter C. Junk and Katherine Kedzierska
Affiliation:
Keywords: Leishmaniasis, antileishmanial drugs, antileishmanial vaccine, immunology, chemotherapy, drug target
Abstract: Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement and fatal systemic infection. WHO estimates that the disease results in 2 million new cases a year, threatens 350 million people in 88 countries and that there are 12 million people currently infected worldwide. Current treatment is based on chemotherapy, which relies on a handful of drugs with serious limitations such as high cost, toxicity, difficult route of administration and lack of efficacy in endemic areas. Pentavalent antimonials have been the mainstay of antileishmanial therapy for over 70 years with second line drugs, Amphotericin B and Pentamidine, used in case of antimonial failure. Since the introduction of miltefosine at the beginning of this century, no new antileishmanial compounds have been approved for human treatment. Leishmaniasis is considered one of a few parasitic diseases likely to be controllable by vaccination. However, to date no such vaccine is available despite substantial efforts by many laboratories. The development of a safe, effective and affordable antileishmanial vaccine is a critical global public-health priority. This review outlines the current status of vaccine development and looks at the currently available chemotherapy as well as examples of drugs in development and different approaches to antileishmanial drug discovery and identification of novel antiparasitic compounds.
Export Options
About this article
Cite this article as:
Kedzierski Lukasz, Sakthianandeswaren Anuratha, Curtis M. Joan, Andrews C. Philip, Junk C. Peter and Kedzierska Katherine, Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines, Current Medicinal Chemistry 2009; 16 (5) . https://dx.doi.org/10.2174/092986709787458489
DOI https://dx.doi.org/10.2174/092986709787458489 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bedside Cardiac Pocus in Emergency Setting: A Practice Review
Reviews on Recent Clinical Trials The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT<sab>2</sab> Receptor
Current Pharmaceutical Design A New Phospholipase A<sub>2</sub> from Lachesis <i>muta rhombeata</i>: Purification, Biochemical and Comparative Characterization with Crotoxin B
Protein & Peptide Letters TRPV4 Agonists and Antagonists
Current Topics in Medicinal Chemistry Prophylactic Neuroprotection
Current Drug Targets N-Acetylcysteine and Other Preventive Measures for Contrast-Induced Nephropathy in the Intensive Care Unit
Current Medicinal Chemistry From Anti-allergic to Anti-Alzheimer ’ s: Molecular Pharmacology of Dimebon™
Current Alzheimer Research Gymnema sylvestre R. Br., an Indian Medicinal Herb: Traditional Uses, Chemical Composition, and Biological Activity
Current Pharmaceutical Biotechnology Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Epidemiology of Septic Acute Kidney Injury
Current Drug Targets ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Effects of <I>Gentiana lutea</I> Root on Vascular Diseases
Current Vascular Pharmacology Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Upper Airway Resistance Syndrome
Current Respiratory Medicine Reviews Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Current Topics in Medicinal Chemistry Managing Side Effects on Ocular Surface Caused by Glaucoma Eye Drops
Current Medicinal Chemistry Decreasing Arterial Aging by Controlling Blood Pressure Levels and Hypertension: A Step Forward
Current Vascular Pharmacology Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry